260 likes | 414 Views
Tumour Working Group and Cancer Clinical Leads Forum. Monday 3 rd December 2012. Welcome and Introduction. Prof Arnie Purushotham , LCA Joint Interim Clinical Director Welcome Outline the purpose of the event Housekeeping. Clinical Leadership within the LCA.
E N D
Tumour Working Group and Cancer Clinical Leads Forum Monday 3rd December 2012
Welcome and Introduction Prof Arnie Purushotham, LCA Joint Interim Clinical Director • Welcome • Outline the purpose of the event • Housekeeping
Clinical Leadership within the LCA • Appointment process for Clinical Director and Associate Clinical Director – interviews 11th December 2012 • Appointment process for Pathway Group Chairs • 12 Pathway Groups (tumour specific only) • Covering letter, advert, job description and job specification emailed to CEOs, Medical Directors, Cancer Clinical Leads and Cancer Nurse Leads • Applicants to send a covering letter and CV emailed to Claire Dowling LCA Programme Director • Closing date for applications by 12 noon 24th December 2012 • Interviews to be held week commencing 21st & 28th January 2013 • Interview panel to include Clinical Director, Associate Clinical Director, Programme Director and Cancer Unit representative from the Interim Clinical Board • Questions?
LCA Progress to date • Establishment of the Members Board and appointment of the Independent Chairs for the Members Board and Clinical Board • Progress against the Clinical Plan • 1st Wave responses to the MoC • Pan London agreement on best practice commissioning pathways in colorectal, lung, brain/CNS and breast • LCA wide best practice clinical guidelines in Breast, OG, Lung, AOS, Survivorship & Palliative Care either agreed or in final version ready for implementation January 2013 • Leading voice in pan London informatics agenda driving progress in completeness of staging, SACT, TCR, agreement of commissioning metrics and development of LCA scorecards • Macmillan project progress on Patient Experience, Patient Information, Chemotherapy closer to Home & Survivorship
LCA Progress to date • Emergency presentation audit underway • Improved engagement and communication including the final stages of development of the LCA website, stakeholder engagement forums across the pathway groups, AOS simulation courses • Development of the User Partnership agenda across London • Development of new systems and processes for Peer Review and the wider quality agenda
But there is much more to do…….. • Appointment of Clinical Director & Associate Clinical Director • Establishment of remaining pathway groups and appointment of tumour-specific Pathway Group Chairs • Delivery of the MoC recommendations in all pathway groups • Promoting prevention and early detection of cancer by supporting GPs and public health messages • Development of the early diagnosis agenda & LCA endoscopy • Delivery of significant improvement in patient experience and patient information across all pathway groups • Development and delivery of the LCA Medicines and Chemotherapy agenda including chemotherapy closer to home • Mental Health and Psychological medicine • LCA Cancer research and training agenda • Engagement with the CCGs • Development and implementation of a communications strategy • Improved collaborative working across south and west London
Commissioning and strategic priorities Dr Kate Haire, LCA Clinical Commissioning
Cancer Commissioning Teams and London Cancer Programme governance structure Operating structure from 1 April 2013
Commissioning of cancer services Model of Care for Cancer Services (NHS London 2010) London Cancer Programme: Strategic Themes • Improving Early Detection • Delivering care closer to home • Consistency of care • Consolidation of services • Delivering productivity and efficiency
LCA Strategic Priorities • Work with London Cancer Programmes to develop 3 year plan for delivery of Model of Care • LCA Clinical Service Plan • LCA Strategic Priorities: Pathway specific and cross cutting priorities • Key issues • Flexibility to take account of emerging priorities • Work of London Cancer Integrated Cancer System • Commissioning arrangements from 2013 • Resources • Wider political context
Preparation for Peer Review Mr Nick Hyde, Cancer Director St George’s Healthcare NHS Trust
LCA Peer Review Progress • Transition of the SE, SW & NW Cancer Network provider functions to the LCA • Mapping of current peer review measures across to LCA structures and processes • LCA Peer Review Transition Plan in final draft • Network Board measures transfer to Joint Development Group due to composition and function of JDG • Existing TWG arrangements remain in place with accountability to the Pathway groups and Clinical Board • Approach maintains oversight & guidance to MDTs until 31st March; assurance to peer review
LCA Peer Review Progress • From April 1st TWG meetings will be replaced with Pathway Group led quarterly tumour specific clinical forums – ensures compliance to 1c measures • These quarterly forums will ensure clinical governance is at the heart of the LCA and will facilitate - clinical audit/clinical effectiveness - patient safety/ patient experience - clinical research - training and education - user involvement and service improvement - vertical communication
LCA Peer Review 2013/14 • Collaborative partnership working with NCAT • Development of a “Skinny” Peer Review– essential components to assure quality standards, systems and processes across the LCA • Development of a Pathway Group Constitution to include: - operational policy - an annual report - work plan • Any Questions?
NCAT Plans and Legacy Ms Ruth Bridgeman, National Programme Director, Peer Review
New Improvement Body (nIB) • Will bring together several legacy organisations • NHS Institute • NHS Improvement • National Cancer Action Team • End of Life Care Programme • NHS Diabetes and Kidney • National Technology Adoption Centre • Work programme will be based around priorities identified by the 5 Domain Directors • Julian Hartley appointed as Interim Managing Director
Business Continuity • Some programmes of work will transfer to the nIB • Some programmes will close because the work is completed • Some programmes will need to continue and a suitable host will need to be found for it i.e. National Cancer Peer Review Programme • Some programmes will be discontinued • We need to capture the learning from all the work we have done. • We need to ensure that the learning is passed on to successor organisations
Transition Delivery Partner (TDP) • Will be established to continue some of the work of existing programmes and to commence delivery on new areas of work • TDP will exist for a period up to one year from April 2013 to March 2014 • Work programme will emerge from the nIB Business Plan • It is proposed that the National Cancer Peer Review Programme will initially form part of the TDP
Change Presentation title and date in Footer dd.mm.yyyy Developing the future Peer Review Programme • Greater focus on Outcomes • Using Service Profiles • Limited data available currently • Fewer Measures • Some process measures will be required • Minimising the evidence required • Operational Policy • Annual Report • Work Programme • Greater Transparency of the reports • My Cancer Treatment
Peer Review – break out session Mr Nick Hyde, Cancer Director St George’s Healthcare NHS Trust
Break out session – 30 mins brainstorm 15 mins feedback session What are the essential components of Peer Review? • Innovative ways of working • What’s new that can be applied to Peer Review in 2013 • Essential documentation • Essential structures, systems and processes • Essential feedback mechanisms • Assurance across 17 provider organisations
Closing Remarks Mr Justin Vale, Joint Interim Clinical Director